CD274 and neoplasm: Moreover, as immune checkpoint inhibitors exploit the critical role of PD-L1/PD-1 and CTLA-4/CD80/CD86 axes in the evasion of immune surveillance, it is a normal consequence that the expression of PD-L1 on tumor cells is a sine qua non for their clinical efficacy [31].